Corynebacterium glucuronolyticum

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Corynebacterium glucuronolyticum is a Gram-positive, non-spore-forming, facultatively anaerobic, non-motile, coryneform bacterium. It has been detected in at least 3 gut microbiome compilation studies or metastudies. The DNA G+C content is 52-58%. Corynebacterium glucuronolyticum is probably a rare gut coloniser. (Gherardi2015; Bernard2012Bergey)



  • This organism has been recovered from clinical sources (prostatitis, cervix, urine, blood, vagina - CCUG) and human faeces. The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread. It is an opportunistic pathogen. A possible gut commensal.
    • QUIRKS
  • Nonlipophilic.
    • GENERAL CHARACTERISTICS (Gherardi2015); (Bernard2012Bergey);
    Character Response
  • 🌡
  • Temperature tolerance:
  • grows at 37℃;
  • H+
  • Acid from carbohydrates usually produced:
  • glucose; sucrose;
  • ±
  • Strain-dependent acid from carbs:
  • ribose; xylose; maltose;
  • Active enzymes:
  • acid phosphatase; catalase; cystine arylamidase; esterase C4; esterase lipase C8; β-glucuronidase; Leu arylamidase;
  • ±
  • Strain-dependent active enzymes:
  • alkaline phosphatase; α-glucosidase; β-glucosidase; phosphoamidase;
    • SPECIAL FEATURES
    Character Response
  • ✗
  • Haemolysis:
  • absent
  • ±
  • Nitrate:
  • strain dependent
    • RESPONSE TO ANTIBIOTICS (Gherardi2015); (Goldstein2006b);
    Class Active Resistant
  • Penicillins:
  • penicillin G;
  • amoxicillin-clavulanic acid; penicillin; piperacillin-tazobactam;
  • Cephalosporins:
  • cefotetan;
  • Tetracyclines:
  • tetracycline;
  • Quinolines:
  • ciprofloxacin;
  • levofloxacin; nalidixic-acid;
  • Aminoglycosides:
  • gentamicin;
  • Polypep/ketides:
  • rifampicin;
  • Vancomycins:
  • vancomycin; dalbavancin;
  • Miscellaneous antibiotics:
  • daptomycin; linezolid;
  • clindamycin; colistin;

  • Lagier, J.-C., Armougom, F., Million, M., Hugon, P., Pagnier, I., Robert, C., Bittar, F., Fournous, G., Gimenez, G., Maraninchi, M., Trape, J.-F., Koonin, E. V., La Scola, B., & Raoult, D. (2012). Microbial culturomics: paradigm shift in the human gut microbiome study. Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 18(12), 1185–1193.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Actinobacteria Class:  Actinomycetia Order:  Corynebacteriales Family:  Corynebacteriaceae Genus:  Corynebacterium Gram stain:  + O2 Relation.:  facultatively anaerobic Spore:  No spore Motility:  Sessile Morphology:  Coryneform
    Health:  Unknown
    Source:  clinical sources (prostatitis, cervix, urine, blood, vagina - CCUG) and human faeces
    DNA G+C(%):  52-58
    Mid T(℃):  37(+)
    		Aesculin:  vr Urea:  vr Gelatin:  neg
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Glucose:  + Ribose:  d Xylose:  d Lactose:  vr Maltose:  d Sucrose:  + Glycogen:  neg Mannitol:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Catalase:  + Ac-β-glcamnd:  neg α-Fucosidase:  neg α-Galactosidase:  neg β-Galactosidase:  vr α-Glucosidase:  d β-Glucosidase:  d β-Glucuronidase:  + α-Mannosidase:  neg CystineAA:  + LeuAA:  + AlkalineP:  d AcidP:  + Esterase(C4):  + EstLip(C8):  + Lipase(C14):  neg Phosphoamidase:  d
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    Augmentin:  R(MIC50): >8, MIC90: >8, RNG: (0.06–>8)
    penicillin:  R(MIC50): >8, MIC90: >8, RNG: (0.06–>8)
    penicillin_G:  S(MIC50): 0.03, MIC90: 0.12, RNG: (0.03-0.12)
    piper-taz:  R(MIC50): >32, MIC90: >32, RNG: (0.125–>32)
    imipenem:  Var(MIC50): 0.25, MIC90: >8, RNG: (0.06–>8)
    meropenem:  Var(MIC50): 0.25, MIC90: >8, RNG: (0.06–>8)
    cefotetan:  R(MIC50): >32, MIC90: >32, RNG: (2–>32)
    gentamicin:  Res
    erythromycin:  Var(MIC50): 0.5, MIC90: 8, RNG: (0.06-64)
    linezolid:  S(MIC50): 0.25, MIC90: 0.25, RNG: (0.12-0.5)
    ciprofloxacin:  Sens
    levofloxacin:  R(MIC50): 8, MIC90: >8, RNG: (0.125–>8)
    nalidixic-acid:  Res
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    tetracycline:  Res
    dalbavancin:  S(MIC50): 0.25, MIC90: 1, RNG: (0.03–1)
    vancomycin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.25–0.5)
    rifampicin:  Sens
    clindamycin:  R(MIC50): >8, MIC90: >8, RNG: (2–>8)
    daptomycin:  S(MIC50): 0.125, MIC90: 0.5, RNG: (0.06–0.5)
    colistin:  Res

    References

    SPECIFIC REFERENCES FOR CORYNEBACTERIUM GLUCURONOLYTICUM
  • Gherardi2015 - Corynebacterium glucuronolyticum causing genitourinary tract infection: Case report and review of the literature.
  • Bernard2012Bergey - Bergey's manual of systematic bacteriology. Vol. 5, The Actinobacteria. Part A & B. Corynebacteriaceae, Genus I. Corynebacterium
  • Goldstein2006b - In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR CORYNEBACTERIUM GLUCURONOLYTICUM
  • Dubourg2013 - The gut microbiota of a patient with resistant tuberculosis is more comprehensively studied by culturomics than by metagenomics.
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • ...............................
    • Added: April 08, 2021